Abdominal Distension: What Could Be Causing It

Distension vs. Bloating: Why the Distinction Matters

Bloating is a subjective sensation of abdominal fullness or pressure. Distension is an objective, measurable increase in abdominal circumference. They often overlap, but they can occur independently, and the clinical workup differs depending on which one predominates.

A 2023 Rome Foundation Global Epidemiology Study published in Gastroenterology estimated that functional abdominal bloating and distension affect approximately 3.5% of the global population when applying Rome IV criteria, with higher rates in women than men 1. Patients who report visible distension without subjective bloating are more likely to have an organic cause such as ascites, organomegaly, or a pelvic mass. Conversely, patients who feel bloated but show no girth change often have visceral hypersensitivity, a hallmark of disorders of gut-brain interaction.

The Rome IV classification system separates functional abdominal bloating/distension (FABD) from IBS. FABD requires recurrent symptoms on at least one day per week for three months without meeting IBS criteria 2. This distinction shapes treatment. A patient with isolated distension and no pain responds differently to therapy than one with pain-predominant IBS.

Clinicians at the Mayo Clinic have noted that "abdominal distension confirmed by imaging or physical exam should always prompt a search for a structural or metabolic cause before attributing it to a functional diagnosis" 3.

The Five Mechanistic Categories of Abdominal Distension

Every case of true distension falls into one (or more) of five pathophysiologic buckets: gas, fluid, fat, fetus/fetal tissue, or a mass (sometimes taught as the "5 Fs" plus obstruction). Understanding which mechanism is at play directs the entire diagnostic pathway.

Excess intraluminal gas accounts for the majority of intermittent distension. Gas production rises with fermentable carbohydrate intake, small intestinal bacterial overgrowth (SIBO), or impaired gas transit. A study using abdominal CT volumetry found that patients with functional distension retained 65% more intestinal gas after a standard meal compared to healthy controls 4.

Intra-abdominal fluid (ascites) produces gradual, persistent distension. The most common cause worldwide is cirrhosis, responsible for roughly 85% of ascites cases in Western populations 5. Cardiac failure, nephrotic syndrome, tuberculosis, and peritoneal carcinomatosis account for the remainder.

Organomegaly or mass lesions create focal or diffuse distension. Hepatomegaly, splenomegaly, ovarian tumors, uterine fibroids, and retroperitoneal masses all belong here. Adipose redistribution, including visceral fat accumulation from metabolic syndrome or Cushing syndrome, produces a more gradual change in girth. Bowel obstruction, whether mechanical or functional (ileus), causes acute distension paired with nausea, vomiting, and altered bowel habits.

Functional Causes: IBS, FABD, and Gut-Brain Dysfunction

Functional disorders are the most frequent explanation for chronic, intermittent distension in outpatient gastroenterology clinics. IBS alone affects 5-10% of the global population, and visible distension occurs in up to 76% of IBS patients during symptom flares 6.

The pathophysiology involves disordered gas handling rather than gas overproduction alone. Patients with IBS and functional distension show abnormal diaphragmatic descent and anterior abdominal wall relaxation during episodes, a phenomenon captured on electromyography and CT imaging 7. Their abdomens protrude not because they contain dramatically more gas, but because the muscles that normally contain that gas behave differently.

Visceral hypersensitivity compounds the problem. Balloon distension studies demonstrate that IBS patients perceive pain at significantly lower rectal volumes (approximately 24 mL) compared to healthy subjects (approximately 45 mL), indicating amplified sensory signaling along the gut-brain axis 8.

Treatment of functional distension follows a stepwise approach. The low-FODMAP diet, developed at Monash University, reduces bloating and distension symptoms in 50-80% of IBS patients within 2-6 weeks 9. Patients who fail dietary therapy may benefit from rifaximin (550 mg three times daily for 14 days), which reduced bloating scores by 36.7% vs. 28.7% for placebo in the TARGET 3 trial (N=2,579) 10. Prokinetic agents such as prucalopride (2 mg daily) can help when slow transit contributes to gas retention.

Biofeedback therapy targeting abdominophrenic dyssynergia has shown particular promise. A randomized controlled trial of 48 patients with functional distension found that biofeedback corrected the abnormal muscular response in 83% of participants, reducing abdominal girth by a mean of 3.9 cm 11.

Small Intestinal Bacterial Overgrowth (SIBO)

SIBO deserves its own section because it sits at the intersection of functional and organic disease. It is defined as bacterial colonization of the small intestine exceeding 10^3 colony-forming units per milliliter on jejunal aspirate, or a positive glucose or lactulose hydrogen breath test 12.

Prevalence estimates vary widely. A meta-analysis of 50 studies reported SIBO in 36.7% of IBS patients versus 9.3% of healthy controls (OR 3.7 to 95% CI 2.3-6.0) 13. Risk factors include proton pump inhibitor use, prior abdominal surgery, diabetes mellitus with gastroparesis, and connective tissue disorders such as systemic sclerosis.

SIBO causes distension through excess fermentation of carbohydrates by misplaced colonic-type bacteria, generating hydrogen, methane, or hydrogen sulfide. Methane-predominant overgrowth (now termed intestinal methanogen overgrowth, or IMO) is particularly associated with constipation and objective distension.

Standard treatment is rifaximin 550 mg three times daily for 14 days. For methane-predominant cases, the combination of rifaximin plus neomycin is more effective than rifaximin alone, with breath test normalization rates of 85% versus 63% 14. Recurrence rates remain high (up to 44% at nine months), which is why addressing the underlying motility disorder or anatomic predisposition matters as much as the antibiotic course.

Ascites: When Fluid Is the Problem

New-onset ascites is never benign until proven otherwise. The American Association for the Study of Liver Diseases (AASLD) practice guideline states that "every patient with new-onset ascites should undergo diagnostic paracentesis" 5. This is a strong recommendation, not optional.

The serum-ascites albumin gradient (SAAG) is the single most useful test on ascitic fluid. A SAAG of 1.1 g/dL or greater indicates portal hypertension with 97% accuracy 15. Causes include cirrhosis (by far the most common), heart failure, Budd-Chiari syndrome, and portal vein thrombosis. A SAAG below 1.1 g/dL points to peritoneal carcinomatosis, tuberculosis, nephrotic syndrome, or pancreatic ascites.

Physical exam can detect ascites when the volume exceeds roughly 500 mL. Shifting dullness has a sensitivity of about 77% and specificity of 72% for ascites detection 16. Point-of-care ultrasound dramatically improves detection sensitivity to above 95% even for small-volume ascites, and the AASLD recommends it as a first-line tool.

Dr. Patrick S. Kamath of the Mayo Clinic has written that "the development of ascites marks a critical transition in the natural history of cirrhosis, with one-year mortality rising from <5% in compensated disease to approximately 20% following the first episode of ascites" 17.

Management of cirrhotic ascites begins with sodium restriction (less than 2 g/day) and diuretics: spironolactone 100 mg daily and furosemide 40 mg daily, titrated in a 100:40 ratio up to maximums of 400 mg and 160 mg respectively. Refractory ascites (affecting roughly 10% of patients) requires serial large-volume paracentesis or transjugular intrahepatic portosystemic shunt (TIPS) placement.

Gynecologic Causes in Women

Abdominal distension in women of reproductive age always warrants consideration of gynecologic pathology. Ovarian masses, including both benign and malignant tumors, can grow to substantial size before producing symptoms beyond a gradual increase in abdominal girth.

Ovarian cancer presents with abdominal distension or bloating in 60-70% of cases, often for months before diagnosis 18. The insidious nature of these symptoms means that ovarian cancer is diagnosed at Stage III or IV in roughly 75% of patients.

The National Comprehensive Cancer Network (NCCN) recommends that women with persistent abdominal distension lasting more than 12 days in a given month, especially when accompanied by pelvic or abdominal pain, difficulty eating, or urinary urgency, should undergo transvaginal ultrasound and serum CA-125 testing 19.

Large uterine fibroids (leiomyomas) are another common cause. Fibroids exceeding 5 cm in diameter can produce visible abdominal distension. They affect up to 70% of White women and 80% of Black women by age 50 20. Treatment options include GnRH agonists for temporary shrinkage, uterine artery embolization, and myomectomy or hysterectomy for definitive management.

Bowel Obstruction: The Surgical Emergency

Acute abdominal distension accompanied by colicky pain, vomiting, and obstipation signals bowel obstruction until imaging proves otherwise. Small bowel obstruction (SBO) accounts for roughly 15% of emergency department admissions for abdominal pain, and adhesions from prior surgery cause 60-75% of cases 21.

CT with intravenous contrast is the imaging study of choice, with sensitivity of 92-94% and specificity of 96% for detecting high-grade SBO 22. The critical finding is the "transition point," the location where dilated proximal bowel meets decompressed distal bowel. Signs of ischemia (mesenteric haziness, bowel wall thickening, reduced enhancement, pneumatosis) demand urgent surgical consultation.

Large bowel obstruction, most commonly from colorectal carcinoma in adults, produces a different clinical picture: more gradual distension, less vomiting, and massive colonic dilation on imaging. Cecal diameter exceeding 12 cm on plain film indicates imminent perforation risk. Pseudo-obstruction (Ogilvie syndrome) mimics mechanical obstruction but has no structural blockage. It responds to neostigmine 2 mg IV over 3-5 minutes, which resolves acute colonic dilation in approximately 90% of cases 23.

Diagnostic Workup: A Structured Approach

The initial evaluation of abdominal distension should be systematic and guided by acuity. Acute onset (hours to days) demands a different tempo than chronic, intermittent symptoms persisting for months.

History should establish onset, duration, relationship to meals, associated GI symptoms (pain pattern, bowel habit changes, nausea, early satiety), menstrual history in women, alcohol intake, liver disease risk factors, medication use (especially opioids and anticholinergics), and weight change. Progressive distension with weight loss is concerning for malignancy. Distension with weight gain may suggest fat deposition, hypothyroidism, or early fluid accumulation.

Physical exam should include inspection (visible peristalsis suggests obstruction; caput medusae suggests portal hypertension), auscultation (hyperactive tinkling sounds in obstruction; absent sounds in ileus), percussion (tympany suggests gas; shifting dullness suggests fluid), and palpation (organomegaly, masses, tenderness).

First-line labs include a complete blood count, comprehensive metabolic panel (liver enzymes, albumin, creatinine), lipase, and thyroid-stimulating hormone. In women, a pregnancy test and CA-125 are appropriate. If ascites is detected, diagnostic paracentesis should follow immediately 5.

Imaging depends on clinical suspicion. Abdominal ultrasound is ideal for detecting free fluid, hepatomegaly, biliary pathology, and pelvic masses. CT abdomen and pelvis with contrast is the study of choice when obstruction, perforation, or occult malignancy is suspected. Hydrogen breath testing is appropriate for suspected SIBO. Anorectal manometry and balloon expulsion testing can identify pelvic floor dysfunction contributing to gas retention.

Red Flags That Require Urgent Evaluation

Not every patient with distension needs emergent workup. But certain features should accelerate the timeline from weeks to hours.

Absent bowel sounds combined with distension suggest ileus or late-stage obstruction. Rebound tenderness or rigidity points toward peritonitis. Fever with distension raises concern for spontaneous bacterial peritonitis in patients with known ascites, a diagnosis with 20-30% in-hospital mortality if untreated 24. New-onset jaundice with distension suggests decompensated liver disease. Hemodynamic instability with distension may indicate intra-abdominal hemorrhage, ruptured ectopic pregnancy, or perforated viscus.

The general rule: if distension is acute, painful, and worsening over hours, the patient belongs in an emergency department, not an outpatient clinic.

Treatment Depends Entirely on the Cause

There is no single treatment for abdominal distension because there is no single cause. Therapy must target the underlying mechanism.

For functional distension and IBS-related symptoms, the evidence base supports the low-FODMAP diet as first-line dietary therapy, with a number needed to treat (NNT) of approximately 5 for symptom improvement 9. Peppermint oil (182 mg enteric-coated capsules, three times daily) reduces IBS bloating with an NNT of 3 based on a meta-analysis of 12 trials 25. Simethicone provides mild relief for gas-related symptoms but has limited efficacy data for true distension.

For SIBO, rifaximin remains the standard. For ascites, the combination of sodium restriction and diuretics achieves adequate control in roughly 90% of patients 5. For bowel obstruction, adhesiolysis resolves the problem when conservative management (nasogastric decompression, IV fluids, bowel rest) fails after 48-72 hours. For gynecologic masses, surgical referral is the definitive step.

Patients prescribed GLP-1 receptor agonists such as semaglutide or tirzepatide should be aware that delayed gastric emptying is a class effect. The STEP-1 trial (N=1,961) reported nausea in 44.2% of participants receiving semaglutide 2.4 mg, and abdominal distension was among the gastrointestinal side effects noted during dose escalation 26. Dose titration over 16-20 weeks minimizes these effects.

Patients with persistent, unexplained distension lasting more than four weeks should receive a referral to gastroenterology for further evaluation including endoscopy, cross-sectional imaging, and motility testing as indicated.